BMS preps filings for leukaemia maintenance therapy CC-486Celgene’s pipeline has delivered another new drug filing for Bristol-Myers Squibb, thanks to positive results for oral azacitidine Share XBMS preps filings for leukaemia maintenance therapy CC-486https://pharmaphorum.com/news/bms-preps-filings-for-leukaemia-maintenance-therapy-cc-486/
Real-world data backs Kymriah’s safety profile, says NovartisWith more competition looming for its CAR-T therapy Kymriah, Novartis has pointed to new data that show the Share XReal-world data backs Kymriah’s safety profile, says Novartishttps://pharmaphorum.com/news/real-world-data-backs-kymriahs-safety-profile-says-novartis/
LentiGlobin gene therapy for sickle cell on course for filing, says bluebirdIt has been an amazing year for patients with sickle cell disease (SCD) with two new drug approvals Share XLentiGlobin gene therapy for sickle cell on course for filing, says bluebirdhttps://pharmaphorum.com/news/lentiglobin-gene-therapy-for-sickle-cell-on-course-for-filing-says-bluebird/
ASH19: AZ’s Calquence throws gauntlet down to ImbruvicaAstraZeneca’s resurgent cancer division could have another winner on its hands. Stellar data with newly-approved BTK inhibitor Calquence Share XASH19: AZ’s Calquence throws gauntlet down to Imbruvicahttps://pharmaphorum.com/news/ash19-azs-calquence-throws-gauntlet-down-to-imbruvica/
Novo Nordisk builds in haemophilia with Bluebird Bio gene editing dealAnxious not to be left behind in the haemophilia market, Novo Nordisk has forged an alliance with Bluebird Share XNovo Nordisk builds in haemophilia with Bluebird Bio gene editing dealhttps://pharmaphorum.com/news/novo-nordisk-builds-in-haemophilia-with-bluebird-bio-gene-editing-deal/
Sobi stays on its acquisitive streak with $915m Dova dealSweden’s Sobi has added another already-marketed product to its rare disease portfolio via a $29 per share takeover Share XSobi stays on its acquisitive streak with $915m Dova dealhttps://pharmaphorum.com/news/sobi-stays-on-its-acquisitive-streak-with-915m-dova-deal/
J&J gets okay for a third first-line Darzalex combo in USJohnson & Johnson continues to extend the use of its Darzalex therapy in newly-diagnosed multiple myeloma patients, getting Share XJ&J gets okay for a third first-line Darzalex combo in UShttps://pharmaphorum.com/news/jj-gets-okay-for-a-third-first-line-darzalex-combo-in-us/
GSK hires former Genentech expert for AI unitGlaxoSmithKline has hired computational drug design specialist Dr Kim Branson to expand its artificial intelligence and machine learning Share XGSK hires former Genentech expert for AI unithttps://pharmaphorum.com/news/gsk-hires-former-genentech-expert-for-ai-unit/
Catalyst’s rival to NovoSeven hits the mark in phase 2 haemophilia trialCatalyst Biosciences is a step closer to challenging Novo Nordisk’s NovoSeven in the haemophilia A and B market Share XCatalyst’s rival to NovoSeven hits the mark in phase 2 haemophilia trialhttps://pharmaphorum.com/news/catalysts-rival-to-novoseven-hits-the-mark-in-phase-2-haemophilia-trial/
